申请人:Dana-Farber Cancer Institute, Inc.
公开号:EP2902030A1
公开(公告)日:2015-08-05
The invention features compositions for treating or preventing a neoplasia. More specifically, the invention provides thienotriazolodiazepine compounds for disrupting the interaction of a BET family polypeptide comprising a bromodomain with chromatin (e.g., disrupting a bromodomain interaction with an acetyl-lysine modification present on a histone N-terminal tail).
本发明的特征是用于治疗或预防肿瘤的组合物。更具体地说,本发明提供了噻吩三唑二氮杂卓化合物,用于破坏包含溴多聚酶链的 BET 家族多肽与染色质的相互作用(例如,破坏溴多聚酶链与存在于组蛋白 N 端尾巴上的乙酰-赖氨酸修饰的相互作用)。